Journal of the American Medical Directors Association
October 19, 2026 · via Europe PMC
Public Health Impact of Adjuvanted RSVPreF3 Vaccination Among US Adults Aged ≥60 Years Residing in Long-Term Care Settings.
La EM, Graham J, Grace M, Zarkadoulas E, Shah N.
AI summary — for doctors, generated from the abstract only
Modelling suggests RSV vaccination with adjuvanted RSVPreF3 could prevent many cases, hospitalizations and deaths among older long-term care residents.
What was studied
Static multicohort Markov model of 2.1 million US adults aged 60+ in long-term care, simulating 5 years of adjuvanted RSVPreF3 vaccination (378,656 vaccinated) versus no vaccination using real-world uptake.
Key findings
- About 33,989 fewer RSV cases, including 26,302 fewer lower respiratory tract disease cases.
- 11,634 fewer hospitalizations, 1556 fewer ED visits and 1355 fewer RSV-related deaths.
- Number needed to vaccinate to avoid one RSV-LRTD case was 14.
Clinical relevance
Medical directors and clinicians in long-term care have a quantified rationale for prioritizing RSV vaccination for residents.
Who should care
Limitations
These are model-based projections dependent on assumptions and inputs, and the abstract does not indicate manufacturer independence.
Make sure eligible long-term care residents are offered RSV vaccination.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Objectives
Adults aged ≥60 years and adults with certain health conditions are at increased risk for severe respiratory syncytial virus (RSV) disease, which can have a substantial clinical burden. Residents in long-term care settings often have multiple risk factors, including age ≥60 years, underlying health conditions, and/or frailty, compounding risk for severe RSV disease. This study evaluated the public health impact of adjuvanted RSV prefusion F3 (RSVPreF3) vaccination on averted RSV disease burden.
Design
Public health impact analysis using a static, multicohort Markov model.
Setting and participants
United States (US) adults aged ≥60 years residing in long-term care settings.
Methods
Adjuvanted RSVPreF3 vaccination vs no vaccination was simulated over 5 years using real-world RSV vaccination uptake data. Other model inputs have been previously validated and reported. This analysis estimated avoided RSV-related health outcomes due to vaccination, as well as the number needed to vaccinate (NNV) to avoid RSV-related outcomes.
Results
Among the modeled 2,113,600 US adults aged ≥60 years residing in long-term care settings, 378,656 were simulated to receive 1 dose of adjuvanted RSVPreF3. RSV vaccination resulted in 33,989 fewer RSV cases, including 7688 fewer RSV-upper respiratory tract disease cases and 26,302 fewer RSV-lower respiratory tract disease cases (RSV-LRTD). Avoided healthcare resource use included 19,639 fewer outpatient visits, 1556 fewer emergency department visits, and 11,634 fewer hospitalizations. RSV-related deaths declined by 1355 over 5 years, alongside 7221 and 6043 fewer discounted life years and quality-adjusted life years lost, respectively. To avoid 1 RSV-LRTD case, the estimated NNV was 14 individuals.
Conclusions and implications
Adjuvanted RSVPreF3 vaccination avoided a substantial number of negative health outcomes among US adults aged ≥60 years residing in long-term care settings, providing evidence of its impact as a prevention strategy. Future efforts are needed to ensure that long-term care residents have access to RSV vaccination.
DOI
10.1016/j.jamda.2026.106406
PMID
42896317
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed